Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | EMB-09 |
| Synonyms | |
| Therapy Description |
EMB-09 is a bispecific antibody targeting CD274 (PD-L1) and TNFRSF4 (OX-40), which potentially induces antigen-specific T-cell activation leading to increased antitumor immune activity (PMID: 39575565). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| EMB-09 | EMB09|EMB 09 | OX40 Antibody 15 PD-L1/PD-1 antibody 132 | EMB-09 is a bispecific antibody targeting CD274 (PD-L1) and TNFRSF4 (OX-40), which potentially induces antigen-specific T-cell activation leading to increased antitumor immune activity (PMID: 39575565). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05263180 | Phase I | EMB-09 | A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. | Unknown status | AUS | 1 |